Skip to main content
. 2021 Jul 14;20:15347354211032283. doi: 10.1177/15347354211032283

Figure 3.

Figure 3.

Coronal view of Subject 3ʹs 18F-flurodeoxyglucose positron emission tomography (FDG-PET) imaging before (Baseline + VLCD, 11/2019) and after (1/2020) combination therapy with alpelisib, a very low carbohydrate diet (VLCD), and sodium glucose co-transporter 2 inhibitor (SGTL2i).